Results 151 to 160 of about 8,510 (199)

Liquid Biopsy in Lung Cancer: Tracking Resistance to Targeted Therapies. [PDF]

Cancers (Basel)
Urtecho SB, Jimenez Munarriz B, Rabey MR, Leighl NB.   +3 more
europepmc   +1 more source

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases. [PDF]

Med Sci (Basel)
Shalata W, Naamneh R, Najjar W, Abu Amna M, Asla M, Agbarya A, Brenner R, Abu Jama A, Abu Yasin N, Abu Juda M, Abu Zeid EED, Rouvinov K, Yakobson A.   +12 more
europepmc   +1 more source

Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment Resistance. [PDF]

Int J Mol Sci
Wilson D, Jayappa S, Parker L, Ocal E, Tanaka T, Gokden M, Bielamowicz K.   +6 more
europepmc   +1 more source

Phase IV clinical trials for the treatment of non-small cell lung carcinoma (NSCLC): A systemic review from 2020-2025. [PDF]

Saudi Med J
Kariri YA, Alqasmi MH, Alqahtani BS.
europepmc   +1 more source

Case Report: A rare case of ALK-KIF5B gene fusion benefited from treatment with lorlatinib. [PDF]

Front Oncol
Luo Y, Ouyang W.
europepmc   +1 more source

Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database. [PDF]

Sci Prog
Zhao W, Jin X, Li Y, Peng H, Jiang J.
europepmc   +1 more source

A real-world pharmacovigilance analysis of ALK inhibitor-associated pleural and pericardial effusion using the FDA Adverse Events Reporting System (FAERS) database from 2013 to 2024. [PDF]

PLoS One
Frey C.
europepmc   +1 more source

Tyrosine-kinase inhibitors for lung or breast cancer and drug-drug interactions: a clinical guide. [PDF]

Oncol Rev
Santamaria F, Roberto M, Maltese G, Nicolella F, Torchia A, Buccilli D, Di Civita MA, Giancontieri P, Marinelli D, Cirillo A, Bianco V, Verrico M, Botticelli A, Santini D.   +13 more
europepmc   +1 more source

Long-term efficacy and improved overall survival of lorlatinib in anaplastic lymphoma kinase-rearranged lung cancer: is cure a dream or a reality? [PDF]

Transl Lung Cancer Res
Horio Y, Kuroda H, Sasaki E, Masago K.
europepmc   +1 more source